ABSTRACT

Every country has its own set of laws and regulations governing pharmaceutical products; these restrictions are nearly identical with minor variances. Failure of a drug at any step, from discovery to development to marketing, results in a significant loss, not only financially and in terms of the organization's reputation, but also in terms of public health. Any company that wants to sell its products to a specific government agency should have a thorough understanding of the rules and regulations, though regulatory authorities can provide strategic counsel in the case of extremely harsh judgments. A company's regulatory department must eliminate the risk by displaying clinically safe and effective drug items properly. They must also accept responsibility for producing high-quality drug items in accordance with rules. The regulatory department serves as a link between the country's regulatory authorities and the Rising populations due to low death rates, as well as a focus on the development of cutting-edge drugs, are predicted to accelerate market development in pharmerging countries. China, Russia, and India are likely to hold a significant portion of the pharmaceutical market among the 17 most important pharmerging countries. To appreciate the profile of pharmerging countries, special evaluation processes was industrialized, and let us use the examples of Brazil, India, China, the United States, and some European countries to understand the current trend. According to a study, the percentage organization's numerous departments. It occurs during every stage of a drug's development, as well as after approval and during commercialization. Keywords: Pharmaceutical Product Design, Development, and Commercial Manufacturing, development of generic drugs History, approval of new drug
Publication date: 01/12/2022

https://ijbpas.com/pdf/2022/December/MS_IJBPAS_2022_6690.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2022/11.12.6690